Eledon Pharmaceuticals, Inc. ELDN 深 沪

Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 45.95 percent. This is a 84.38 percent increase over losses of $(0.64) per share from the

03-20 05:13

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

03-19 21:10

美股夜盘 | Health In Tech, Inc. Class A涨52.94%，ZenaTech, Inc.涨18.42%

Health In Tech, Inc. Class A涨52.94%；ZenaTech, Inc.涨18.42%；万达生物制药涨10.81%

03-18 13:02

Eledon reports 100% insulin independence in 10 patients in tegoprubart islet transplant trial

Eledon reports 100% insulin independence in 10 patients in tegoprubart islet transplant trial Eledon reported updated results from an investigator-initiated pilot study of tegoprubart, an anti-CD40L monoclonal antibody, used in a calcineurin inhibitor-free immunosuppression regimen for allogeneic is

03-16 19:05

Eledon Pharma rises on FDA orphan status for lead asset

Eledon Pharmaceuticals (ELDN) added ~7% in the premarket on Tuesday after the U.S. Food and Drug Administration (FDA) issued its Orphan Drug designation for the company's lead candidate, tegoprubart. ...

03-10 20:18

BUZZ-U.S. STOCKS ON THE MOVE-Crypto stocks, MiNK Therapeutics, AtaiBeckley

BUZZ-U.S. STOCKS ON THE MOVE-Crypto stocks, MiNK Therapeutics, AtaiBeckley Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 10 (Reuters) - U.S. stock index futures ticked up

03-10 19:58

BUZZ-Eledon rises as FDA grants orphan drug status for liver transplant rejection drug

BUZZ-Eledon rises as FDA grants orphan drug status for liver transplant rejection drug ** Shares of  Biotech firm Eledon Pharmaceuticals ELDN.O rise 5.17% to $3.05 premarket ** Co says FDA granted orphan drug status for tegoprubart to prevent liver transplant rejection; the condition involves the bo

03-10 19:11

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Eledon Pharmaceuticals announced that its CEO and CSO will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026. The webcast can be registered in advance and a replay will be available on the company's website. Eledon is developing immune-modulating therapies, with its lead product tegoprubart targeting CD40L for treating life-threatening conditions like kidney transplantation and ALS. More in...

03-04 21:05

Eledon Pharma To Present 24-Month Follow-Up Data From Eight Patients Enrolled In Phase 1b Trial Long-Term Extension Evaluating Tegoprubart In Kidney Transplantation At 2026 ASTS Winter Symposium

Data from eight participants continue to support safety and tolerability profile of tegoprubartMean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24

01-23 20:06

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Eledon Pharmaceuticals announced 24-month follow-up data from eight kidney transplant patients in an ongoing Phase 1b trial extension, demonstrating the safety and tolerability of tegoprubart, an anti-CD40L antibody. The data showed an increase in mean eGFR from 67.0 to 74.2 mL/min/1.73 m² over the study period with no episodes of biopsy-proven acute rejection or graft loss. Eledon will present the findings at the American Society of Transplant S...

01-23 12:00